New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:05 EDTBAYRY, ONXXBayer, Onyx announce Phase 3 DECISION trial of Nexavar meets primary endpoint
Bayer HealthCare Pharmaceuticals (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that a Phase 3 trial of Nexavar tablets in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. Adverse events were generally consistent with the known profile for Nexavar. Data from this study are expected to be presented at an upcoming medical meeting.
News For BAYRY;ONXX From The Last 14 Days
Check below for free stories on BAYRY;ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
15:05 EDTBAYRYBayer non-cystic fibrosis bronchiectasis treatment gets FDA orphan designation
According to a post on the FDA's website, Bayer's ciprofloxacin dry powder inhaler to treat non-cystic fibrosis bronchiectasis received orphan designation. Reference Link
April 10, 2014
07:24 EDTBAYRYInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
April 9, 2014
07:09 EDTBAYRYReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use